Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cephalexin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources
PubMed1983

[Double-blind comparison of cefadroxil and cephalexin granules in the treatment of impetigo].

A double-blind clinical comparison of cefadroxil granules (CDX) and a long-acting preparation of cephalexin granules (L-CEX) was conducted in the treatment of impetigo in children. The long-acting cephalexin preparation was composed of 3 parts of granules soluble in the stomach and 7 parts of those soluble in the intestine. Drugs were administered at 3 different doses depending on the body weight of patients (Group I: less than 10 kg, Group II: between 10 kg and 20 kg, Group III: over 20 kg). Overall clinical evaluation by attending doctors: CDX group scored slightly better but not statistically significant results. Evaluation of usefulness: CDX group scored slightly better but not statistically significant results. Partially standardized evaluation: CDX scored statistically significantly higher points in the evaluation of total cases and Group II on Day 5, and Group II on Day 7. Cumulative points through Day 5 and Day 7 were not statistically significant. Follow-up evaluation by attending doctors: CDX group got a better result in total cases and Group II on day 3, and in total cases on days 5 and 7. Otherwise there was no statistically significant difference. Incidence of side effects was not significantly different between the 2 drug groups. As shown in Fig. 1, CDX was administered on rising in the morning, after lunch, and at bed time whereas L-CEX was given on rising and at bed time when the patients were relatively in fasting condition. This may have reduced the expected merit of L-CEX and some reserve is required in the interpretations of the results shown herein.

Adolescent↗
PubMed1984

Comparison of in vitro antibacterial activity of four oral cephems: cephalexin, cefaclor, cefatrizine and cefadroxil.

The in vitro antibacterial activity of four oral cephems: cephalexin, cefaclor, cefatrizine and cefadroxil against clinical isolates of staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa was compared by agar dilution method. All drugs had comparable antistaphylococcal activity. Cefatrizine and cefaclor were more active than cephalexin and cefadroxil against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. All four drugs were relatively inactive against isolates of Enterobacter species and indole-positive Proteus. However, cefatrizine demonstrated the greatest activity of the four oral cephems against these organisms. None of these oral cephems was active against Serratia marcescens or Pseudomonas aeruginosa.

Bacteria↗
PubMed1978

[Treatment of pulmonary infections with cephalexin (author's transl)].

The efficacy of Cephalexin--an oral cephalosporine--was assessed in 20 children with pulmonary infections including bronchopneumonia and infiltrative peribronchitis in an open study. In 16 patients prompt resolution of clinical and radiological signs was observed. The drug was well tolerated, there were no side effects or allergies to be demonstrated. Among the therapeutic agents for infections of the respiratory tract cephalexin should be considered among the antibiotics of first choice.

Bronchitis↗
PubMed1983

Cephalexin in the therapy of infections of the urinary tract.

Cephalexin is an oral cephalosporin which is widely used in the treatment of urinary tract infections. It is readily absorbed from the gastrointestinal tract and achieves high concentrations in the urine, where it retains its full activity against the organisms commonly responsible for urinary tract infections. It also achieves adequate serum levels. Cephalexin is essentially nontoxic at recommended doses, and its clinical efficacy in urinary tract infections has been repeatedly documented in numerous studies since 1971.

Acute Disease↗
PubMed1982

[Cefroxadine and cephalexin in urinary tract infections. Kinetics of germ elimination].

Cefroxadine and cephalexin were compared in a double-blind study in patients with complicated urinary tract infections. Patients were treated orally with 1 g t.i.d. for five days. Bacterial counts in the urine were determined 1, 3 and 8 hours after the first dose and on the second, third and fifth day of treatment. A decrease in the bacterial population below 10(4) organisms/ml of urine was taken as being indicative of chemotherapeutic effect. Urine specimens were inactivated enzymatically before culture to eliminate any residual cephalosporin. A significant reduction in the bacterial count was seen one and three hours after the first dose, and, to a much greater extent, after eight hours. Reduction in the bacterial count was more frequent in the group treated with cefroxadine. The results during the first eight hours indicate that cefroxadine kills more rapidly than cephalexin, which is in agreement with the experimental findings. Whether the transient differences observed in the rates of inhibition are of clinical relevance remains uncertain.

Adolescent↗
PubMed1980

[Fundamental and clinical studies of sustained release cephalexin (L-Keflex) in the field of oral surgery (author's transl)].

L-Keflex is a newly manufactured cephalexin product in order to maintain effective blood level of the drug for a long period of time. The results of the fundamental and clinical studies are as follows: 1. Mean blood levels of the drug after its single oral dose of 1 g in fasting in 22 cases before operations were: 7.19 mcg/ml at 2 hours (peak), 4.35 mcg/ml at 4 hours, 4.21 mcg/ml at 6 hours, 2.47 mcg/ml at 8 hours and 1.81 mcg/ml at 12 hours, respectively. Existence of the drug in blood was observed for a long period of time. 2. The distribution into the tissues of L-Keflex was generally good. The tissue levels in 19 of 22 samples ranged from 1.30 to 18.0 mcg/g, but 3 samples did not detect the drug in the tissues. Tissue level/blood level ratios were 0.19 approximately 2.67. 3. Half of 30 cases with mild dental infections was treated with a daily dose of 1 g with clinical response of 60.0%, and the other half with 2 g was 78.6% in clinical response. The overall efficacy rate was 69.0%. 4. As a side effect of the drug, only one of 52 cases (fundamental 22 cases, clinical 30 cases) complained of edema on both eyelids. No. abnormality was observed in blood finding, hepatic and/or renal function. From the above results, it is considered that L-Keflex is an effective antibiotic product in infections in the field of oral surgery. Also, L-Keflex has an advantage in that its administration frequence (b.i.d) is less than that of regular cephalexin (q.i.d.).

Adolescent↗
PubMed1980

[Double-blind comparison of L-keflex and cephalexin (Keflex) in dental infections (author's transl)].

In order to evaluate efficacy and safety of L-Keflex (granule form of sustained release cephalexin), a double blind study comparing it with Keflex (capsule of regular cephalexin) was conducted in dental infections. Evaluable cases in adults for efficacy of the drugs were 196 consisting of 97 for L-Keflex and 99 for Keflex. Those in children were 19 (8 for L-Keflex and 11 for Keflex). There were no significant differences in background of the patients and severity of the diseases between both groups (L-Keflex and Keflex groups). The daily doses used in both groups were 1,000 mg in adults and 500 mg in children, respectively. The dose was given in two divided doses for L-Keflex group and in four divided doses for Keflex group. Following are evaluation by the committee members for the study: Adults 1. Clinical response rate at final therapy day was 93.8% in L-Keflex group and 92.9% in Keflex group, showing no significant difference between both groups. 2. No significant difference in severity of subjective and objective symptoms between both groups was observed at each therapy day. 3. Side effects were found in 6.7% of 105 patients receiving L-Keflex and in 5.6% of 107 patients with Keflex, and there was no significant difference between both groups. As the side effects, gastrointestinal symptoms, rash and itching were observed, but no any other side effects were found in both groups. Children 1. As shown in the above, number of the cases enough to evaluate statistically was not obtained, but all of both groups clinically responded to the drugs. 2. As for side effects diarrhea was observed in only one patient of Keflex group consisting of 12 patients. In the patient, however, discontinuation of the drug was not required and the side effect disappeared during the therapy. From the above results, L-Keflex (granule) is judged to have more convenience than Keflex (capsule) in that (1) it can be administered with b.i.d. regimen and (2) it can be easily taken in dental patients such as patients having difficulty in opening mouth of swallowing pain.

Adolescent↗
PubMed1982

Treatment of acute uncomplicated urinary tract infections by cephalexin, with special reference to the antibody-coated bacteria.

In 68 college-age females with acute uncomplicated urinary tract infections (UTI), ACB testing revealed that 36.8% of the infections were localized in the kidney and 63.2% in the urinary bladder. Sixty-two patients who completed 10 days of therapy with cephalexin showed a clinical and bacteriologic cure on the last day of therapy. Ninety-seven percent of patients were free of UTI at 1 week post therapy. Cephalexin appeared to be equally effective in treatment of both ACB-positive and ACB-negative infections. Antibody-coated bacteria did not correlate with symptoms, response to therapy, or rate of recurrences.

Adult↗
PubMed1997

Cephalexin rash in infectious mononucleosis.

The ampicillin rash occurring in cases of infectious mononucleosis is well documented. Similar phenomena have also been observed with other antibiotics. The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed. The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis. The mechanism by which these eruptions occur is not completely understood, although there are many interesting theories. Perhaps rashes during infectious mononucleosis in association with other antibiotics are actually more common, but just not recognized. A heightened awareness of this possibility may therefore lead to recognition of more cases and further understanding of this entity.

Adult↗
PubMed1996

Contrast between the pharmacokinetics of two formulations of cephalexin after intramuscular administration in cattle.

Two commercial formulations of cephalexin were administered intramuscularly to five heifers and five bulls in a balanced crossover design. Statistically significant and clinically important differences were detected between the two formulations of cephalexin. These results suggest that 24 h dose intervals would be appropriate with only one of the formulations and that the recommended dose rates for each product may need to be reviewed.

Journal Article↗
PubMed1978

In vitro susceptibility of Haemophilus influenzae to sulfamethoxazole-trimethoprim and cefaclor, cephalexin, and cephradine.

Sulfamethoxazole-trimethoprim and three oral cephalosporins, cefaclor, cephalexin, and cephradine, were evaluated in vitro as possible alternatives to chloramphenicol in the treatment of non-central nervous system infections due to ampicillin-resistant Haemophilus influenzae. Sixty-four isolates of H. influenzae, including 31 beta-lactamase-positive strains, were tested by the agar dilution method. All strains were inhibited by 0.78/0.039 mug sulfamethoxazole-trimethoprim per ml and by 0.78 mug of chloramphenicol per ml. At 6.25 mug/ml, 100, 11, and 3% of all strains were inhibited by cefaclor, cephalexin, and cephradine, respectively. Thus, on the basis of drug concentrations presumably achievable in serum, 100% of strains were susceptible to sulfamethoxazole-trimethoprim, chloramphenicol, and cefaclor. However, a considerable inoculum effect was noted with both beta-lactamase-positive and -negative strains, when tested with sulfamethoxazole-trimethoprim; the minimal inhibitory concentrations of cefaclor were only slightly affected. Also, synergistic effects of sulfamethoxazole-trimethoprim, sulfamethoxazole-erythromycin, and sulfamethoxazole-cefaclor were seen when combinations were tested against both beta-lactamase-positive and -negative strains, as determined by minimal inhibitory concentrations measured by the broth dilution method and by killing curve analyses. These results support further evaluation of these combinations and of cefaclor alone for the treatment of non-central nervous system infections due to H. influenzae.

Cephalosporins↗
PubMed1970

Changes in gut flora after cephalexin treatment.

Eighteen patients with urinary tract infection were treated with cephalexin orally. Absorption was variable, between 29 and 89% of the total daily dose being excreted in the urine in 24 hours. A significant number of patients became faecal carriers of Pseudomonas aeruginosa compared with a control group who received no antibiotics. Four of the cephalexin-treated patients acquired a strain of Ps. aeruginosa known to be present in food from the hospital diet kitchen and one developed a urinary tract infection with this strain.

Aged↗
PubMedDate not supplied

Simultaneous liquid chromatographic analysis of the beta-lactam antibiotics cefazolin, cefadroxil, cephalexin, ampicillin, and cephradine in solution.

A liquid chromatographic method was developed for the determination of nanogram quantities of 5 broad-spectrum structurally related beta-lactam antibiotics (cefazolin, cefadroxil, cephalexin, cephradine, and ampicillin) in solution. The method uses a C18 reversed-phase column, UV absorption (240 nm) detection, and an aqueous mobile phase containing isopropyl alcohol and acetic acid. Relative resolution between the antibiotic peaks ranged from 1.7 to 5.9 for all peaks. Chromatographic retention times were 2.97, 3.92, 4.57, 5.37, and 6.56 min for cefazolin, cefadroxil, cephalexin, ampicillin, and cephradine, respectively. Accuracy, precision, linearity, and long term analytical reproducibility were determined by statistical analysis. Use of the proposed method to evaluate the degradation of cephradine solutions stored at room temperature illustrated its potential as a stability-indicating assay.

Anti-Bacterial Agents↗
PubMed1980

Enzymatic biosynthesis of cephalexin.

The reaction kinetics of the enzymatic synthesis of cephalexin from 7-aminodeacetoxy cephalosporanic acid and phenylglycine methylester was studied using the synthesizing enzyme obtained from Xanthomonas citri. The activation energy, Km values for 7-aminodeacetoxy cephalosporanic acid and phenylglycine methylester, and Ki value for phenylglycine methylester were determined as 8.63 kcal/mol, 3.7mM, 14.5mM, and 70mM, respectively. The enzyme was found to be constitutive and susceptible to deactivation.

Amidohydrolases↗
PubMed1991

Effects of ethanol on the pharmacokinetics of cephalexin and cefadroxil in the rat.

Data are presented on the effect of ethanol on the intestinal absorption and excretion in rats of two beta-lactam antibiotics, cephalexin (CFX) and cefadroxil (CFD). A recirculating perfusion technique within an antibiotic concentration range of 0.5 to 50 mM was used. Ethanol was administered either in an acute form into the intestine or in a chronic form as a 15% drinking solution for 2 months. The results are normalized in relation to the metabolic body weight, intestinal length, and osmotic conditions. Acute ethanol treatment decreases the antibiotic absorption; biliary excretion of CFD is increased, while urinary excretion of CFX is lowered. Chronic treatment shows slight negative effects on the absorption of CFX and CFD. Results are interpreted on the basis of the effect of ethanol on biological membranes. Enhanced urinary excretion after acute ethanol treatment, as well as differences between transport mechanisms, are invoked to explain these effects.

Administration, Oral↗
PubMedDate not supplied

The in vitro activity of ampicillin, amoxicillin, cephalexin, nitrofurantoin, sulphadiazine and trimethoprim against Streptococcus agalactiae isolated from urinary and other infections.

The minimum inhibitory concentrations (MIC) for 100 strains of Streptococcus agalactiae varied as follows: ampicillin 0.1 to greater than 1 mg/l, amoxicillin 0.03 to 0.5 mg/l, cephalexin 2 to greater than 16 mg/l, nitrofurantoin 8 to greater than 64 mg/l, sulphadiazine all greater than 500 mg/l and trimethoprim less than 3.9 to greater than 250 mg/l. The MICs of the beta-lactams were not affected by inoculum density. Amoxicillin was 2.5 times as active as ampicillin. Sulphadiazine and trimethoprim acted synergistically, and the average factor of potentiation exceeded 5.9. The growth curves and drug susceptibilities of 19 strains isolated from urine were similar to those of the 81 strains isolated from other sources.

Amoxicillin↗
PubMed1987

Antibiotic as ligand. Coordinating behavior of the cephalexin towards Zn(II) and Cd(II) ions.

The complex formation equilibria of Zn(II) and Cd(II) with cephalexin have been studied through potentiometric titrations. Experimental data were analyzed using the least squares computer program SUPERQUAD. The stability constants were 1g beta ZnCEX+ = 2.40, 1g beta Zn(CEX)(OH) = -4.54, 1g beta CdCEX+ = 2.18, and 1g beta Cd(CEX)(OH) = -5.18 (I = 0.1 M NaNO3), CEX complexes of formulae Zn(CEX)2(3)H2O and Cd(CEX)(OH)H2O have been synthesized and characterized by elemental analysis, IR spectra, conductivity measurements, and electronic and NMR spectra. The thermal behavior of the synthesized compounds were studied by TGA and DTA. We conclude that the metal ion interacts with the amido group of CEX.

Cephalexin↗